IQST - IQSTEL Reports 1H 2026 Revenue of $207 Million, Up 59% Year-Over-Year, as Stockholders' Equity Reaches $17.2 Million

IQSTEL (NASDAQ:IQST) said it expects to exceed an $8 million adjusted EBITDA run rate this quarter after the planned Ultranet acquisition closes. The deal is expected to add about $130 million in annual revenue and $4.5 million in annual net income, lifting annualised revenue run rate above $500 million and expanding to ~30 countries. IQSTEL targets higher-margin AI, cybersecurity and fintech services as a main earnings driver from 2027.

iQSTEL Inc (IQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. iQSTEL Inc. - Form 8-K - July 13, 2026 false 0001527702 0001527702 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

iQSTEL (NASDAQ:IQST) shares rose about 54% to $1.36 after the company reported preliminary first-half 2026 revenue growth of about 59% and said the Ultranet acquisition should lift profitability. iQSTEL expects an annual revenue run rate toward $500 million, EBITDA above $8 million, and improved cash flow. Next update is Aug. 13.

Samsung Electronics and SK hynix are expected to post record Q3 operating profits, driven by high memory demand and supply shortages. Samsung's profit is estimated at 111.38 trillion won, up 815.47% YoY, while SK hynix's profit is forecast at 78.13 trillion won, up 586.34% YoY. Both companies are focusing on HBM for AI semiconductors, exacerbating general-purpose DRAM shortages.

Morgan Stanley raised its price target for TD Synnex Corp (NYSE:SNX) to $359 from $334, citing stronger-than-expected earnings, accelerating growth, and improving operating leverage. The company's fiscal third-quarter revenue and EPS beat estimates by 13%-21%, with fourth-quarter guidance 12%-25% above expectations. Analysts also increased fiscal 2027 and 2028 earnings estimates by 12%-15%, driven by enterprise AI demand and new hyperscaler programs.

Eli Lilly (LLY) reports that Foundayo, its oral GLP-1 drug, now accounts for about one-third of new patients starting the treatment. Foundayo generated $98 million in Q2 revenue, contributing to Lilly's total Q2 revenue of $23.0 billion, up 48% YoY. Lilly raised its 2026 revenue guidance to $85 billion-$87 billion and is investing $6.5 billion in a new Houston facility to produce Foundayo and other medicines.